Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.9400
- TODAY'S CHANGE (%)0.0400 (1.0256%)
- Bid / Lots3.9000/ 4
- Ask / Lots4.1100/ 5
- Open / Previous Close3.9300 / 3.9000
- Day Range
- 52 Week Range
- Volume97,843
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 651 | 3.93 |
| 09:34 ET | 1879 | 3.9 |
| 09:39 ET | 350 | 3.96 |
| 09:45 ET | 456 | 3.98 |
| 09:48 ET | 3239 | 4 |
| 09:50 ET | 911 | 4 |
| 09:52 ET | 922 | 3.98 |
| 09:56 ET | 425 | 3.9664 |
| 10:06 ET | 185 | 3.96 |
| 10:08 ET | 482 | 3.965 |
| 10:10 ET | 137 | 3.94 |
| 10:12 ET | 2500 | 3.9799 |
| 10:26 ET | 100 | 3.98 |
| 10:30 ET | 500 | 3.99 |
| 10:32 ET | 100 | 3.965 |
| 10:33 ET | 400 | 3.96 |
| 10:35 ET | 100 | 3.99 |
| 10:39 ET | 200 | 3.99 |
| 10:42 ET | 200 | 4 |
| 10:50 ET | 140 | 3.9662 |
| 11:27 ET | 100 | 4 |
| 11:40 ET | 1200 | 4 |
| 11:45 ET | 500 | 3.975 |
| 11:49 ET | 200 | 3.98 |
| 11:54 ET | 805 | 3.96 |
| 12:00 ET | 306 | 3.9605 |
| 12:02 ET | 100 | 3.97 |
| 12:14 ET | 290 | 3.94 |
| 12:34 ET | 863 | 3.94 |
| 12:36 ET | 2035 | 3.9001 |
| 12:39 ET | 100 | 3.925 |
| 12:43 ET | 445 | 3.91 |
| 12:50 ET | 836 | 3.91 |
| 12:56 ET | 150 | 3.905 |
| 01:01 ET | 255 | 3.9048 |
| 01:03 ET | 200 | 3.895 |
| 01:10 ET | 754 | 3.9 |
| 01:15 ET | 100 | 3.9 |
| 01:17 ET | 2645 | 3.93 |
| 01:19 ET | 300 | 3.93 |
| 01:21 ET | 100 | 3.93 |
| 01:24 ET | 100 | 3.93 |
| 01:26 ET | 300 | 3.93 |
| 01:28 ET | 356 | 3.96 |
| 01:30 ET | 220 | 3.94 |
| 01:35 ET | 400 | 3.96 |
| 01:37 ET | 2000 | 3.96 |
| 01:39 ET | 1000 | 3.94 |
| 01:44 ET | 200 | 3.97 |
| 01:46 ET | 215 | 3.95 |
| 01:51 ET | 400 | 3.96 |
| 01:53 ET | 1422 | 3.945 |
| 02:00 ET | 3000 | 3.95 |
| 02:02 ET | 200 | 3.97 |
| 02:04 ET | 200 | 3.93 |
| 02:06 ET | 500 | 3.95 |
| 02:08 ET | 300 | 3.97 |
| 02:09 ET | 100 | 3.93 |
| 02:11 ET | 980 | 3.93 |
| 02:13 ET | 200 | 3.95 |
| 02:15 ET | 200 | 3.93 |
| 02:22 ET | 200 | 3.93 |
| 02:24 ET | 100 | 3.945 |
| 02:27 ET | 200 | 3.93 |
| 02:29 ET | 534 | 3.93 |
| 02:31 ET | 955 | 3.93 |
| 02:40 ET | 200 | 3.94 |
| 02:42 ET | 400 | 3.96 |
| 02:44 ET | 300 | 3.94 |
| 02:45 ET | 600 | 3.945 |
| 02:54 ET | 200 | 3.93 |
| 02:58 ET | 400 | 3.93 |
| 03:02 ET | 300 | 3.94 |
| 03:03 ET | 200 | 3.935 |
| 03:05 ET | 300 | 3.92 |
| 03:12 ET | 300 | 3.92 |
| 03:16 ET | 1801 | 3.935 |
| 03:18 ET | 400 | 3.935 |
| 03:21 ET | 100 | 3.95 |
| 03:23 ET | 183 | 3.92 |
| 03:25 ET | 2341 | 3.94 |
| 03:27 ET | 1939 | 3.955 |
| 03:32 ET | 961 | 3.94 |
| 03:34 ET | 599 | 3.93 |
| 03:41 ET | 100 | 3.92 |
| 03:45 ET | 2654 | 3.97 |
| 03:48 ET | 300 | 3.98 |
| 03:50 ET | 195 | 3.965 |
| 03:52 ET | 8364 | 3.97 |
| 03:54 ET | 824 | 3.95 |
| 03:56 ET | 3877 | 3.94 |
| 03:57 ET | 1819 | 3.95 |
| 03:59 ET | 6856 | 3.94 |
Jul 16, 2024
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund, from 9:00AM ET on Tuesday Jul 16, 2024 by Dow Jones
9:00AM ET on Tuesday Jul 16, 2024 by Dow Jones
Jun 26, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 165.5M | -3.6x | --- |
Metagenomi Inc | 175.0M | -1.7x | --- |
Innate Pharma SA | 184.3M | -20.9x | --- |
AVITA Medical Inc | 263.2M | -5.8x | --- |
Champions Oncology Inc | 65.4M | -9.1x | --- |
Precision BioSciences Inc | 70.4M | -1.8x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $165.5M |
|---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
